Panzytrat ( DrugBank: - )

---

1 disease

告示番号	疾患名（ページ内リンク）	臨床試験数
298	遺伝性膵炎	3

298. 遺伝性膵炎

---

臨床試験数 : 98 /  薬物数 : 180 - (DrugBank : 57) / 標的遺伝子数 : 53 - 標的パスウェイ数 : 142

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT01430234 (ClinicalTrials.gov)	October 2011	1/9/2011	Enzyme Suppletion in Exocrine Pancreatic Dysfunction	Enzyme Substitution in Exocrine Pancreatic Insufficiency; Self Administration Against a Fixed Dose Regimen	Chronic Pancreatitis;Exocrine Pancreatic Insufficiency	Drug: Panzytrat 25.000 FIP-E units of Lipase	Foundation for Liver Research	Axcan Pharma	Completed	18 Years	90 Years	Both	10	Phase 4	Netherlands
2	EUCTR2010-020303-69-NL (EUCTR)	19/09/2011	19/09/2011	Enzyme substitution in exocrine pancreatic insufficiency; Self administration against a fixed dose regimen. - SAPES	Enzyme substitution in exocrine pancreatic insufficiency; Self administration against a fixed dose regimen. - SAPES	Exocrine pancreatic insufficiency in patients with chronic pancreatitis MedDRA version: 12.1;Level: LLT;Classification code 10041969;Term: Steatorrhoea	Trade Name: Panzytrat Product Name: Panzytrat Product Code: RVG 13760 INN or Proposed INN: pancreatic enzymes Other descriptive name: LIPASE	Erasmus MC	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	20		Netherlands
3	EUCTR2004-002468-89-DE (EUCTR)	28/10/2004	23/09/2004	A RANDOMISED, DOUBLE-BLIND, PLACEBO CONTROLLED PHASE IV TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF PANCREATIN VS. PLACEBO FOR LIPID DIGESTION AND ABSORPTION IN PATIENTS WITH PANCREATIC EXOCRINE INSUFFICIENCY - Pancreatin vs. Placebo in Patients with Pancreatic Exocrine Insufficiency	A RANDOMISED, DOUBLE-BLIND, PLACEBO CONTROLLED PHASE IV TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF PANCREATIN VS. PLACEBO FOR LIPID DIGESTION AND ABSORPTION IN PATIENTS WITH PANCREATIC EXOCRINE INSUFFICIENCY - Pancreatin vs. Placebo in Patients with Pancreatic Exocrine Insufficiency	The purpose of this clinical trial is to evaluate the clinical efficacy and safety of a capsule containing enteric-coated porcine pancreatin microfilm tablets in comparison with placebo in the treatment of pancreatic exocrine insufficiency due to chronic pancreatitis. MedDRA version: 7.0;Level: LLT;Classification code 10033622	Trade Name: Panzytrat 25.000 Product Name: Panzytrat 25.000 Product Code: Pancreatin INN or Proposed INN: Pancreatin	Axcan Pharma S.A.	NULL	Not Recruiting			Female: yes Male: yes	20	Phase 4	Germany